BIO Lays Ethical Foundation For Change In Off-Label Communications
Executive Summary
The industry group's future advocacy around legal and regulatory reforms affecting product sponsor communications with payers and health-care providers will align with four bioethical considerations.
You may also be interested in...
How To Handle Off-Label Promotion: A Guide From PhRMA And BIO
Industry communication principles offer best practices for combating contrary evidence, refuting third-party comparative effectiveness analyses and sharing real-world evidence addressing health outcomes and costs.
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Manufacturer communications with providers and payers could include real-world evidence and pharmacoeconomic information, associations urge.
Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say
While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions